STOCKSCREENR

AIDX

NASDAQ

20/20 Biolabs, Inc. Common Stock

$2.16-0.34(-13.60%)Mkt Cap: $10.61M

Key Stats

Market Cap

$10.61M

P/E Ratio

-6.97

EPS

$-0.31

Dividend Yield

0.00%

52-Week Range

$2.05 — $50.00

Volume

179.69K

Avg Volume

395.06K

Beta

-0.42

Valuation

P/E (TTM)

-6.97

Forward P/E

PEG Ratio

-0.07

P/S (TTM)

14.42

P/B (TTM)

125.37

P/FCF

EV/EBITDA

EV/Sales

Financial Health

ROE (TTM)

-2.53%

ROA (TTM)

-0.64%

ROIC

Gross Margin

0.32%

Operating Margin

-2.14%

Net Margin

Debt/Equity

15.64

Current Ratio

0.79

Growth

EPS Growth (YoY)

Revenue Growth (YoY)

EPS Growth (3Y)

-1.24%

EPS Growth (5Y)

-0.31%

Sales Growth (3Y)

-0.16%

Sales Growth (5Y)

+1.94%

EPS Est (This Year)

EPS Est (Next Year)

Dividends

Dividend Yield

Annual Dividend

Payout Ratio

Frequency

Ex-Dividend Date

Cash/Share

$0.24

Ownership

Institutional %

Inst. Net Change

Insider Net Shares (90d)

Outstanding Shares

4.91M

Float

4.26M

Free Float %

86.80%

About

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

NASDAQ

IPO Date

2023-06-15

Employees

13

CEO

Jonathan Cohen

Index Membership

Website

https://2020biolabs.com

20/20 Biolabs, Inc. Common Stock (AIDX) is a healthcare company in the medical - devices industry listed on the NASDAQ. With a market capitalization of $10.61M, a P/E ratio of -6.97, AIDX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare AIDX against other stocks using dozens of fundamental and technical filters.

Similar Stocks

Frequently Asked Questions

What is 20/20 Biolabs, Inc. Common Stock's P/E ratio?

20/20 Biolabs, Inc. Common Stock (AIDX) has a trailing twelve-month (TTM) P/E ratio of -6.97. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does 20/20 Biolabs, Inc. Common Stock pay a dividend?

No, 20/20 Biolabs, Inc. Common Stock (AIDX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is 20/20 Biolabs, Inc. Common Stock's market cap?

20/20 Biolabs, Inc. Common Stock (AIDX) has a market capitalization of $10.61 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.